|
| Exchange Disseminated Time | Venus Remedies Ltd has informed BSE regarding "Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval"
Announcement:
"The Company achieved yet another landmark by receiving the Market Authorization for GEMCITABINE, one of the key products for the treatment of Cancer via decentralized procedure from Medicine and Healthcare Regulatory Agency (MHRA) U.K, The other countries in the list are Poland, Germany, Slovenia and Portugal for which the same feat has been achieved.
Venus is all set to capture substantial market share by entering the highly lucrative market of Europe as it stands amongst the first few to receive the Market Authorisation for Gemcitabine". Gemcitabine is a $1.5 billion drug world wide with more than 30% market share from Europe.
Gemcitabine is used in the treatment of a variety of cancerous diseases including the cancer of lungs, pancreas, bladder and breast. Gemcitabine, in combination with Cisplatin, recently received FDA & EMEA approval as a first line treatment for lung cancer which is the most common form of cancer worldwide and accounts for 1.2 million fresh cases annually. GEMCITABINE, the only drug approved, has been established as the gold standard drug therapy for Pancreatic cancer (216,000 cases/annum) which has a survival rate of below 3% and is all set for explosive growth and will remain amongst the choicest of drugs even after becoming generic.
The product is available in two strength of 200mg and 1000mg and both the strengths of Venus dossier have been approved by UK MHRA authorities. Venus will produce Gemcitabine from its EU GMP approved Baddi, facility in India and planned to launch the product in UK and Germany along with other EU countries by second quarter of 2011.
With this rare accomplishment Venus Remedies along with its illustrious product range shall now be entering the European Market through its wholly owned subsidiary Venus Pharma Gmbh." |
|
|